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Identity 
Other names: BMND1, EVR1, EVR4, HBM, LR3, 
LRP7, OPPG, OPS, OPTA1, VBCH2 




Genomic size: 136636; genomic sequence: (chr11: 67 
836 684-67 973 319). 
Transcription 
5161 bp mRNA; (NM_002335, 05-oct-2009). 
Pseudogene 
Homo sapiens low density lipoprotein receptor-related 
protein 5-like (LRP5L), transcript variant 1, 
Aliases: DKFZp434O0213, 
NCBI Reference Sequence: NM_182492.2, 
Location: 22q11.23, 




LRP5 contains a large extracellular domain (ECD) 
making up over 85% of the approximately 1600-amino-
acid protein. At the amino terminus of the ECD, four 
beta-propeller motifs and four epidermal growth factor 
(EGF)-like repeats create the binding sites for 
extracellular ligands. These domains are followed by 
three LDLR type A (LA) domains. The intracellular 
domain of LRP5 contains 5 PPPSP motifs, to which 
Axin preferentially binds after phosphorylation of the 
PPPSP motif induced by Wnt ligands. Tamai et al. 
showed that Wnt activates LRP5's homologue, LRP6, 
by inducing LRP6 phosphorylation at the PPP(S/T)P 
motifs, which serve as inducible docking sites for Axin, 
thereby recruiting Axin to the plasma membrane. 
Expression 
Widely expressed, with the highest level of expression 
in the liver. 
 
 
Exon count: 23; coding exon count: 23. 
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Schematic diagram of human LRP5, 1615 aa. (from He et al., 
Development. 2004 Apr;131(8):1663-77). 
Post-translational modification: Phosphorylation of the 
PPPSP motif creates an inducible docking site for 
Axin. Palmitoylation is required for LRP6 to exit the 
endoplasmic reticulum (ER). 
Localisation 
Membrane; single-pass type I membrane protein. 
Function 
Involved in the Wnt/beta catenin signaling pathway, 




The heterozygous LRP5V171 mutation cosegregated 
with high bone density. This gain-of-function mutation 
in LRP5 causes an autosomal dominant disorder 
characterized by high bone density, torus palatinus, and 
a wide, deep mandible.  
In 2001, Gong et al. reported that they identified a total 
of six different homozygous frame-shift or nonsense 
mutations in affected offspring from consanguineous 
families affected by osteoporosis pseudoglioma 
syndrome. They also found homozygous missense 
mutations in affected patients from two other 
consanguineous families and heterozygous nonsense, 
frame-shift, and missense mutations in affected patients 
from four nonconsanguineous families. Many patients 
with this syndrome are also born with severe disruption 
of the ocular structure, phthisis bulbi. 
Jiao et al. reported that homozygous mutations R570Q, 
R752G, and E1367K in LRP5 cosegregated with 
familial exudative vitreoretinopathy (FEVR). 
There are many other papers reporting LRP5 gene 
mutations and SNP polymorphisms that are associated 
with bone density variation, familial exudative 
vitreoretinopathy, obesity, etc. 
Somatic 
Westin's group reported that the tumor-associated 
shorter transcript of LRP5 containing an in-frame 
deletion of 142 amino acids (D666-809) was strongly 
implicated in deregulated activation of the Wnt/beta-
catenin signaling pathway in hyperparathyroid tumors 
and mammary gland tumorigenesis. 
 
Schematic representation of LRP5 mutations; those associated with osteoporosis pseudoglioma (OPPG) syndrome, autosomal-dominant 
familial exudative vitreoretinopathy (FEVR), and various high-bone-density diseases are shown in red, purple, and green, respectively. 
Arrows indicate mutation locations: *, nonsense mutation; fs, frame-shift mutation. (from He et al., Development. 2004 Apr;131(8):1663-
77). 
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Implicated in 
Hyperparathyroid tumors, breast cancer 
Note 
According to Bjorklund's reports, the internally 
truncated human LRP5 receptor is strongly implicated 
in deregulated activation of the Wnt/beta-catenin 
signaling pathway in hyperparathyroid tumors and 
mammary gland tumorigenesis, and thus presents a 
potential target for therapeutic intervention. 
 
The truncation version of LRP5 (LRP5∆666-809) missed the 
last 93 bp of exon 9, all 227 bp of exon 10, and the first 106 bp 
of exon 11. 
Oncogenesis 
Reverse transcription PCR and Western blot analysis 
showed expression of truncated LRP5 in 32 out of 37 
primary hyperparathyroidism (pHPT) tumors (86%) 
and 20 out of 20 secondary hyperparathyroidism 
(SHPT) tumors (100%). 
Truncated LRP5 frequently expressed in breast tumors 
of different cancer stages (58-100%), including 
carcinoma in situ and metastatic carcinoma. Truncated 
LRP5 was required in MCF7 breast cancer cells for the 
nonphosphorylated active beta-catenin level, 
transcription activity of beta-catenin, cell growth in 




LRP5 is required for maintaining the basal lineage of 
mouse mammary tissue (Badders et al., 2009) and for 
mammary ductal stem cell activity and Wnt1-induced 
tumorigenesis (Lindvall et al., 2006).  
LRP5 is a novel marker for disease progression in high-
grade osteosarcoma (Hoang et al., 2004). Dominant 
negative LRP5 showed inhibition of osteosarcoma 





Children with the autosomal recessive disorder 
osteoporosis pseudoglioma syndrome (OPPG) (Gong et 
al., 1996) have very low bone mass and are prone to 
developing fractures and deformation. In addition t the 
skeletal phenotype, many individuals with OPPG have 
eye involvement in the form of severe disruption of the 





Gong et al. found that OPPG carriers have reduced 
bone mass when compared with age- and gender-
matched controls. They demonstrated LRP5 expression 
by osteoblasts in situ and showed that LRP5 can 
transduce Wnt signaling in vitro via the canonical 
pathway. They also showed that a mutant secreted form 
of LRP5 can reduce bone thickness in mouse calvaria 
explant cultures. These data indicate that Wnt-mediat  
signaling via LRP5 affects bone accrual during growth 
and is important for the establishment of peak bone 
mass. 
Ai et al. sequenced the coding exons of LRP5 in 37 
probands suspected of having OPPG on the basis of the 
co-occurrence of severe congenital or childhood-onset 
visual impairment and bone fragility or osteoporosis 
recognized by young adulthood. They measured the 
ability of wild-type and mutant LRP5 to transduce Wnt 
and Norrin signals ex vivo. Each of the seven OPPG 
mutations tested had reduced signal transduction 
relative to wild-type controls. These results indicate 
that early bilateral vitreoretinal eye pathology coupled 
with skeletal fragility is a strong predictor of LRP5 
mutation and that mutations in LRP5 cause OPPG by 
impairing Wnt and Norrin signal transduction. 
In 2008, Yadav et al. identified Tph1, which encodes 
the rate-limiting enzyme in serotonin synthesis, as the 
most highly overexpressed gene in LRP5-/- mice. Tph1 
expression was also elevated in LRP5-/- duodenal cells. 
Decreasing serotonin blood levels normalized bone 
formation and bone mass in LRP5-/- mice, and gut-
specific LRP5 inactivation decreased bone formation in 
a beta-catenin-independent manner. They concluded 
that LRP5 inhibits bone formation by inhibiting 
serotonin production in the gut. 
Cheung et al. identified a family with osteoporosis 
pseudoglioma syndrome due to compound 
heterozygosity of two novel mutations in the LRP5 
gene (W478R and W504C). 
In 2007, Drenser et al. found familial exudative 
vitreoretinopathy and osteoporosis pseudoglioma 
syndrome caused by a mutation in the LRP5 gene. 
Xiong et al. found that LRP5 gene polymorphisms are 
associated with bone mass density in both Chinese and 
whites. The Chinese sample consisted of 733 unrelated 
subjects and the white sample was made up of 1873 
subjects from 405 nuclear families. 
The most frequently studied polymorphisms in LRP5 
are two amino acid substitutions, Val667Met and 
Ala1330Val. A common variant of LRP6, Ile1062Val, 
contributes to fracture risk in elderly men, and is linked 
to coronary heart disease and low BMD. In 2008, Joyce 
et al. confirmed that the two common LRP5 variants 
are consistently associated with BMD and fracture risk
across different white populations, but the LRP6 
variant is not. 
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High bone mass (HBM) 
Note 
Bone mass density (BMD) and fracture rates vary 
among women of differing ethnicities. Most reports had 
suggested that BMD is highest in African Americans, 
lowest in Asians, and intermediate in Caucasians, yet 
Asians have lower fracture rates than Caucasians. 
Finkelstein et al. (2002) assessed lumbar spine and 
femoral neck BMD by dual-energy x-ray 
absorptiometry in 2277 (lumbar) and 2330 (femoral) 
premenopausal or early perimenopausal women (mean 
age, 46.2 yr) participating in the Study of Women's 
Health Across the Nation. When BMD was assessed in 
a subset of women weighing less than 70 kg and then 
adjusted for covariates, lumbar spine BMD was similar 
in African American, Chinese, and Japanese women 
and was lowest in Caucasian women. Femoral neck 
BMD was highest in African Americans and similar in 
Chinese, Japanese, and Caucasians. They also 
suggested that these findings may explain why 
Caucasian women have higher fracture rates than 
African Americans and Asians. 
Cytogenetics 
Little et al. also identified the same Gly171Val 
mutation in the LRP5 gene (G171V; 603506.0013) that 
results in an autosomal dominant high bone mass trait. 
Van Wesenbeeck et al. performed mutation analysis of 
the LRP5 gene in 10 families or isolated patients with 
various conditions of an increased bone density, 
including endosteal hyperostosis. Direct sequencing of 
the LRP5 gene revealed 19 sequence variants. Six 
novel missense mutations (D111Y, G171R, A214T, 
A214V, A242T, and T253I) are located in the amino-
terminal part of the gene, before the first epidermal 
growth factor-like domain, which is the same as for the 
G171V mutation that causes the high-bone-mass 
phenotype and most likely is disease-causing. 
Boyden et al. found that the expression of LRP5V171 did 
not activate signaling in the absence of Wnt-1. The 
activation of the signaling pathway in response to Wnt-
1 was the same with normal and mutant LRP5.They 
also tested the action of the endogenous antagonist f 
Wnt signaling, Dkk-1. Although Dkk-1 inhibited Wnt 
signaling in conjunction with wild-type LRP5, Dkk-1 
inhibition of Wnt signaling was virtually abolished in 
cells expressing LRP5V171. These findings indicated 
that the mutation G171V, located in the first YWTD 
repeat of LRP5, results in increased Wnt signaling 
because of loss of Dkk antagonism to LRP5. 
However, Zhang et al. found that the third YWTD 
repeat (but not the first repeat domain) was requird for 
DKK1-mediated antagonism. They found that the 
G171V mutation disrupted the interaction of LRP5 
with Mesd, a chaperone protein for LRP5/6 that is 
required for transport of the co-receptors to cell 
surfaces, resulting in fewer LRP5 molecules on the cell 
surface. So they think that the G171V mutation may 
cause an increase in Wnt activity in osteoblasts by 
reducing the number of targets for paracrine DKK1 to 
antagonize without affecting the activity of autocrine 
Wnt. 
Ai et al. expressed seven different HBM-LRP5 
missense mutations, including G171V, to delineate the 
mechanism by which they alter Wnt signaling. Each 
mutant receptor was able to reach the cell surface, 
albeit in differing amounts, and transduce exogenously 
supplied Wnt1 and Wnt3a signals. The affinities 
between the mutant forms of LRP5 and Mesd did not 
correlate with their abilities to reach the cell surface. 
All HBM mutant proteins had reduced physical 
interaction with and reduced inhibition by DKK1. 
These data suggest that HBM mutant proteins can 
transit to the cell surface in sufficient quantity o
transduce Wnt signal and that the likely mechanism for 
the HBM mutations' physiologic effects is via reduced 
affinity to and inhibition by DKK1. 
Semenov further showed that LRP5 HBM mutant 
proteins exhibit reduced binding to a secreted bone-
specific LRP5 antagonist, SOST, and consequently are 
more refractory to inhibition by SOST. Further, Bhat 
used structure-based mutation analysis to show the 
importance of LRP5 beta-propeller 1 in modulating 
Dkk1-mediated inhibition of Wnt signaling. 
Familial exudative vitreoretinopathy 
(FEVR) 
Note 
Familial exudative vitreoretinopathy (FEVR) is a well-
defined inherited disorder of retinal vessel development 
(Benson, 1995). It is reported to have a penetrance of 
100%, but clinical features can be highly variable ev n 
within the same family. Severely affected patients may 
be legally blind during the first decade of life, whereas 
mildly affected individuals may not even be aware of 
symptoms and may receive a diagnosis only by use of 
fluorescein angiography. 
Cytogenetics 
As reported by Toomes et al., mutations in LRP5 
within the EVR1 locus can cause FEVR, accounting for 
15% of the patients and indicating that other 
unidentified FEVR genes may be a more significant 
cause of the disease than previously thought. 
Jiao et al. studied three consanguineous families of 
European descent in which autosomal recessive FEVR 
was diagnosed in multiple individuals. Sequencing of 
LRP5 showed, in all three families, homozygosity for 
mutation in LRP5: R570Q, R752G, and E1367K. Thus, 
mutations in the LRP5 gene can cause autosomal 
recessive as well as autosomal dominant FEVR. 
Qin et al. screened 56 unrelated patients with FEVR 
(31 familial and 25 simplex cases) for possible 
mutations in LRP5 and Frizzled 4 (FZD4). Six novel 
mutations in either LRP5 or FZD4 were identified in 
six familial cases. Four novel mutations in LRP5 and 
one known mutation in FZD4 were detected in three 
simplex cases, and two of these patients carried 
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compound heterozygous mutations in LRP5. They also 
demonstrated that reduced bone density is a common 




Obesity is a growing health care problem and a risk
factor for common diseases such as diabetes, heart 
disease, and hypertension. 
LRP5 is highly expressed in many tissues, including 
hepatocytes and pancreatic beta cells. Some evidence 
has shown that LRP5 can bind apolipoprotein E (apoE), 
which raises the possibility that LRP5 plays a role in 
the hepatic clearance of apoE-containing chylomicron 
remnants, a major plasma lipoprotein carrying diet-
derived cholesterol. 
Using LRP5 knock-out mice model, Fujino et al. 
showed that LRP5-deficient islets had a marked 
reduction in the levels of intracellular ATP and Ca2+ in 
response to glucose, and thereby glucose-induced 
insulin secretion was decreased. The intracellular 
inositol 1,4,5-trisphosphate (IP3) production in 
response to glucose was also reduced in LRP5-/- islets. 
The authors suggested that Wnt/LRP5 signaling 
contributes to the glucose-induced insulin secretion in 
the islets. 
Cytogenetics 
Guo et al. performed genotyping of 27 single 
nucleotide polymorphisms (SNPs), spaced 5 kb apart 
on average and covering the full transcript length of the 
LRP5 gene, using samples of 1873 Caucasian people 
from 405 nuclear families. They found that SNP4 
(rs4988300) and SNP6 (rs634008), located in block 2 
(intron 1), showed significant associations with obesity 
and BMI after Bonferroni correction (SNP4: p < 0.001 
and p = 0.001, respectively; SNP6: p = 0.002 and 
0.003, respectively). The common allele A for SNP4 
and minor allele G for SNP6 were associated with an 
increased risk of obesity. Significant associations were 
also observed between the common haplotype A-G-G-
G of block 2 and obesity, BMI, fat mass, and PFM, 
with global empirical values of p < 0.001, p < 0.001, p 
= 0.003 and p = 0.074, respectively. They concluded 
that intronic variants of the LRP5 gene are markedly 
associated with obesity, possibly due to the role of 
LRP5 in the Wnt signaling pathway or lipid 
metabolism. 
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